Dashboard

Eli Lilly and Company

LLYNYSE

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$1.1T

Price$1,196.0352w $625.65 – $1,235.56

Conviction5/ 5

Revenue (TTM)$72.2B

Revenue growth YoY+47.4%

P/E (trailing)42.2

Gross margin83.5%

Operating margin45.9%

Net margin35.0%

52w price change+60.1%

Next earningsAug 5, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

Jul 24
Trial initiationClinicalTrials.gov
Phase 3 trial (NCT07213804) initiated for Sofetabart Mipitecan in platinum-resistant/sensitive ovarian cancer; recruiting status.
Jul 23
Trial initiationClinicalTrials.gov
Phase 3 trial NCT07035093 of Retatrutide (LY3437943) in obesity/overweight with chronic low back pain status updated to ACTIVE_NOT_RECRUITING.
Jul 23
Trial readoutClinicalTrials.gov
Eli Lilly completes Phase 1 study NCT07202871 on absorption of LY3537031.
Jul 22
OtherClinicalTrials.gov
Eli Lilly updates ClinicalTrials.gov NCT06339008 Phase 3 lebrikizumab perennial allergic rhinitis trial status to ACTIVE_NOT_RECRUITING.
Jul 22
OtherClinicalTrials.gov
ClinicalTrials.gov update for phase 1 trial NCT04603001 of oral LY3410738 in IDH1/IDH2-mutant advanced hematologic malignancies; status ACTIVE_NOT_RECRUITING.
Jul 22
Trial initiationClinicalTrials.gov
Eli Lilly Phase 2 trial NCT07641504 of LY4065967 for chronic low back pain listed as not yet recruiting.
Jul 22
OtherClinicalTrials.gov
Phase 1 trial NCT04521686 of LY3410738 in IDH1/IDH2-mutant solid tumors updated to ACTIVE_NOT_RECRUITING status.
Jul 22
OtherClinicalTrials.gov
Phase 3 trial NCT04975308 of imlunestrant ± abemaciclib in ER+ HER2- advanced breast cancer updated to active, not recruiting (sponsor LLY).
Jul 22
OtherClinicalTrials.gov
Phase 2 trial (NCT02711553) of ramucirumab or merestinib in biliary tract cancer updated to active, not recruiting.
Jul 22
Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial (NCT06672939) of Orforglipron in adolescents with obesity or overweight with comorbidities; status recruiting.
Jul 21
Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial NCT07219953 of Brenipatide for Alcohol Use Disorder (RECRUITING).
Jul 21
Ownership changeSEC
Form 4 insider transaction report filed for Eli Lilly executive.
Jul 21
Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial (NCT07219966) of Brenipatide for moderate-to-severe alcohol use disorder; status recruiting.
Jul 21
Ownership changeSEC
SEC Form 4 insider transaction filing.
Jul 21
Ownership changeSEC
Form 4 insider transaction filing for Eli Lilly.
Jul 21
Ownership changeSEC
Form 4 insider transaction filing by Eli Lilly officer or director.
Jul 20
Trial initiationClinicalTrials.gov
Phase 3 trial (NCT06439277) of tirzepatide in adolescents with obesity and comorbidities begins recruiting.
Jul 20
Trial initiationClinicalTrials.gov
Phase 3 trial (NCT06338995) of lebrikizumab in chronic rhinosinusitis with nasal polyps listed as recruiting.
Jul 20
Trial initiationClinicalTrials.gov
Morphic Therapeutic (LLY subsidiary) Phase 2 trial of MORF-057 in Crohn's Disease (NCT06226883) status: RECRUITING
Jul 20
Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial NCT07157774 of Muvalaplin for major CV events in adults with elevated Lp(a); status recruiting.

Not financial advice — research and opinion only. Disclosures